The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramelteon for prevention of postoperative delirium in elderly cancer patients: A randomized, double-blind, placebo-controlled multicenter trial, JORTC-PON02/J-SUPPORT2103/NCCH2103.
 
Ryoichi Sadahiro
Honoraria - Daiichi Sankyo
 
Masanori Enokido
No Relationships to Disclose
 
Yoshinobu Matsuda
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Sanofi
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - Chugai Pharma; Eisai; EPS Corporation; Japan Tobacco Inc; Kowa; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Public Health Research Foundation; Sonire Therapeutics
Speakers' Bureau - Nippon Kayaku
Research Funding - Cordis. (Inst); DAIICHI SANKYO COMPANY, LIMITED. (Inst); Kyowa Kirin Co., Ltd. (Inst); NTT DOCOMO, INC. (Inst); Otsuka (Inst); Solasia Pharma (Inst); TSUMURA & CO. (Inst)
 
Keisuke Ariyoshi
No Relationships to Disclose
 
Shunsuke Oyamada
No Relationships to Disclose
 
Yosuke Uchitomi
Research Funding - Aflac; Daiichi Sankyo; Meiji-Seika Pharma; Shionogi; Susmed
 
Tatsuo Akechi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kowa; Lilly; Lundbeck; Meiji-Seika Pharma; Merck; MSD; Otsuka; Pfizer; Shionogi; Sumitomo Dainippon Pharma; Takeda; Tsumura & Co.; UCB; Viatris
Consulting or Advisory Role - Snom Inc.
Research Funding - Shionogi
Patents, Royalties, Other Intellectual Property - Pending patents: 2020-135195, 2024-516288, 2025-128748Granted patent: 7313617Royalties from Igaku-Shoin
Other Relationship - Tatsuo Akechi serves as the Representative Director of the General Incorporated Association NCU CRESS.
 
Kotaro Hatta
Honoraria - Daiichi Sankyo; Eisai; Janssen; Meiji Seika Kaisha; MSD; Otsuka; Shionogi; Sumitomo Pharma Oncology; Taisho
Consulting or Advisory Role - GEXval; Hisamitsu Pharmaceutical; Lead Chemical; MSD
 
Kazuko Matsumoto
No Relationships to Disclose
 
Takatoshi Hirayama
No Relationships to Disclose
 
Rika Nakahara
No Relationships to Disclose
 
Asao Ogawa
Stock and Other Ownership Interests - delispect
Speakers' Bureau - Chugai Pharma; Eisai
 
Hironobu Hashimoto
Speakers' Bureau - Taiho Pharmaceutical
 
Makoto Maeda
No Relationships to Disclose
 
Asuko Sekimoto
No Relationships to Disclose
 
Tetsufumi Sato
No Relationships to Disclose
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Mitsubishi Tanabe; Noile-Immune Biotech, Inc; Rakuten Medical Japan
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mitsubishi Tanabe Pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst); Zymeworks (Inst)
 
Eiko Saito
No Relationships to Disclose
 
Hiromichi Matsuoka
Speakers' Bureau - Eisai/MSD; Shionogi; Tsumura & Co.